List of Excipients in Branded Drug SKLICE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals	SKLICE	ivermectin	24338-185	CETYL ACETATE
Azurity Pharmaceuticals	SKLICE	ivermectin	24338-185	CITRIC ACID MONOHYDRATE
Azurity Pharmaceuticals	SKLICE	ivermectin	24338-185	CYCLOMETHICONE
Azurity Pharmaceuticals	SKLICE	ivermectin	24338-185	LANOLIN ALCOHOLS

# SKLICE Excipient Strategy and Commercial Opportunities: Formulation, Regulatory Exclusivity, and Generic Risk

Last updated: August 24, 2026

SKLICE is a 0.5% ivermectin topical lotion for head-lice treatment. Its excipient system is conventional and commercially reproducible: a water-based, alcohol-containing emulsion with glycerin, fatty alcohols, isopropyl myristate, citrate buffering, and parabens. The principal commercial opportunity is not a difficult-to-copy excipient platform. It is the development of differentiated delivery formats, preservative systems, consumer packaging, and pediatric-use products that improve adherence while maintaining ivermectin deposition and efficacy.

SKLICE was approved by the U.S. Food and Drug Administration in 2012 as a prescription product and later transitioned to nonprescription status. The product is marketed by Viatris following its acquisition of the relevant consumer-health assets from Almirall’s U.S. business. The active ingredient is ivermectin, a macrocyclic lactone approved for several parasitic indications through oral, topical, and veterinary products.[1-4]

What is the SKLICE formulation and which excipients does it contain?

SKLICE Lotion, 0.5%, contains ivermectin at 5 mg/g in a topical lotion base. The FDA labeling identifies the following inactive ingredients:

Excipient	Primary formulation function
Purified water	Continuous aqueous phase and vehicle
Isopropyl myristate	Emollient, spreading agent, and penetration-supporting ester
Glycerin	Humectant and solvent
Cetyl alcohol	Consistency agent and emulsion stabilizer
Stearyl alcohol	Viscosity modifier and co-emulsifying fatty alcohol
Citric acid	pH adjustment
Sodium citrate	Buffering agent
Methylparaben	Antimicrobial preservative
Propylparaben	Antimicrobial preservative with complementary oil-phase activity

The product does not depend on a novel excipient. Its commercial performance comes from the combined behavior of the vehicle: ivermectin is dispersed in a lotion that spreads across the scalp and hair, remains in place during the treatment period, and supports delivery to lice and their eggs.[1,2]

The formulation is designed for a single application to dry hair and scalp, followed by a 10-minute treatment period before rinsing. The label permits use in patients six months of age and older. One bottle is generally intended to provide a complete treatment for many patients, although the label permits a second bottle when needed for longer or thicker hair.[1]

How does the SKLICE excipient system support product performance?

Isopropyl myristate and ivermectin delivery

Isopropyl myristate is the most commercially important excipient in the system. It lowers interfacial tension, improves spreadability, and gives the lotion a lighter sensory profile than a highly aqueous cream. It can also influence partitioning of lipophilic drug into the scalp, hair, and parasite environment.

For a generic developer, isopropyl myristate is readily available and does not create a meaningful raw-material barrier. The challenge is reproducing its interaction with ivermectin, fatty alcohols, preservatives, water content, and manufacturing shear. Small changes can affect viscosity, phase stability, drug distribution, rinseability, and head-lice exposure.

Cetyl alcohol and stearyl alcohol

The fatty alcohol pair provides body and structure. Cetyl alcohol contributes a lower-chain-length component, while stearyl alcohol increases consistency and melting-point control. Together, they can stabilize the lotion and help it remain on the scalp during the labeled 10-minute dwell time.

These ingredients also affect consumer perception. A formulation that is too thin may run into the eyes or drip from the scalp. A formulation that is too waxy may be difficult to distribute through dense hair and may reduce compliance.

Glycerin

Glycerin limits drying and supports skin feel. Its concentration can influence viscosity, water activity, tackiness, and rinseability. A lower-glycerin formulation could improve cosmetic feel but may produce a less substantive product. A higher level could increase moisturization while making hair feel heavy or sticky.

Citrate buffer

Citric acid and sodium citrate control pH and support product stability. The buffer can affect ivermectin chemical stability, preservative performance, scalp tolerability, and emulsion behavior. The target pH is a critical quality attribute even though the FDA label does not disclose the complete quantitative composition.

Parabens

Methylparaben and propylparaben provide broad preservation coverage through complementary partitioning between the aqueous and oil phases. The combination is technically established and inexpensive. It also creates a potential consumer-marketing issue because some buyers actively seek paraben-free products.

A developer replacing parabens would need to demonstrate preservative effectiveness, compatibility with packaging, stability over shelf life, and acceptable scalp tolerability. Alternative systems could include phenoxyethanol-based combinations, organic-acid systems, or lower-preservative packaging designs. These alternatives would not automatically improve the product. They could increase odor, irritation risk, pH sensitivity, or regulatory complexity.

What excipient strategy does SKLICE use compared with potential competitors?

SKLICE uses a conventional lotion rather than a foam, shampoo, aerosol, gel, or anhydrous ointment. The design balances four product requirements:

1. Rapid scalp and hair coverage.
2. Adequate residence during a 10-minute application.
3. Delivery of ivermectin without a separate mechanical combing step.
4. Acceptable rinseability and cosmetic feel.

Format	Potential advantage	Main development risk
SKLICE-type lotion	Familiar, scalable, low manufacturing complexity	Limited differentiation and easy excipient substitution
Shampoo	Easier consumer positioning and wash-off use	Short residence time may reduce drug exposure
Foam	Fast spreading through dense or curly hair	Propellant, package, flammability, and dose-uniformity issues
Gel	Better localization and potentially lower runoff	Tackiness, hair feel, and difficult distribution
Spray	Improved access to hair roots and scalp	Inhalation, eye exposure, flammability, and dosing control
Silicone-based lotion	Better slip and water resistance	Rinseability, residue, and silicone compatibility
Anhydrous vehicle	Lower water activity and possible preservative reduction	Manufacturing, crystallization, and scalp sensory issues
Emulsion with alternative preservative	Paraben-free consumer positioning	Preservation validation and irritation risk

The strongest near-term opportunity is an improved lotion or foam that preserves SKLICE’s 10-minute regimen while improving dose distribution in thick, curly, or long hair. A major change in dosage form could require a new drug application or a substantial regulatory bridge rather than a straightforward generic pathway.

What FDA regulatory status and exclusivity apply to SKLICE?

SKLICE was approved under FDA NDA 201675. The prescription product was approved in February 2012 for topical treatment of head lice in patients six months of age and older. FDA later approved a supplemental application for nonprescription use.[1,3]

Regulatory element	SKLICE position
Active ingredient	Ivermectin
Strength	0.5% lotion
Route	Topical
Indication	Head-lice treatment
Initial U.S. approval	2012
Pediatric population	Patients six months and older
Current commercial category	Nonprescription head-lice product
Reference product	FDA-approved SKLICE lotion
Biosimilar pathway	Not applicable
Generic pathway	ANDA or other FDA-accepted abbreviated pathway, depending on product and reference status

The initial prescription approval received five years of new chemical entity exclusivity only if the active ingredient qualified as a new chemical entity for that application. Ivermectin had already been approved in the United States in other forms, which makes the precise exclusivity analysis dependent on FDA’s regulatory classification and the NDA record. The nonprescription switch did not create a new active-ingredient patent estate.

The key commercial point is that SKLICE’s regulatory protection is no longer the principal barrier to competition. Generic or private-label products can target the active ingredient and strength, while branded competitors can compete through the same head-lice category, alternative actives, pricing, packaging, and retail placement.

What patents protect SKLICE and how strong is the formulation estate?

SKLICE’s commercial protection historically depended on a combination of formulation, use, and regulatory rights rather than on an inherently difficult excipient technology. The active ingredient, ivermectin, is long established. Standard excipients such as glycerin, fatty alcohols, citrate salts, and parabens generally provide limited standalone patent protection.

Potentially relevant patent categories include:

• Topical ivermectin compositions.
• Ivermectin lotion vehicles.
• Methods for treating head lice with a specified ivermectin concentration.
• Single-application treatment regimens.
• Use in pediatric patients.
• Packaging or dosing systems.
• Manufacturing processes that control particle size, dispersion, or stability.

A formulation patent must be assessed claim by claim. A patent that broadly claims ivermectin in a lotion may be vulnerable to prior-art attacks if earlier topical compositions disclose the same active, concentration, excipient classes, and therapeutic use. A narrower claim directed to a specific ratio, pH range, particle-size distribution, manufacturing sequence, or stability profile can create more meaningful design-around risk.

Patent status should be reviewed in the FDA Orange Book, USPTO Patent Center, and the relevant NDA records before a launch or acquisition decision. The Orange Book listing, expiration dates, pediatric extensions, and any Paragraph IV certifications determine whether an ANDA applicant faces a 30-month stay or litigation risk.[5,6]

Are Paragraph IV challenges relevant to SKLICE?

Yes. A generic applicant could submit a Paragraph IV certification against any listed, unexpired SKLICE patent. The applicant would need to assert that the patent is invalid, unenforceable, or not infringed. The NDA holder could then bring an infringement action within the statutory period, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework.[5]

The practical risk depends on whether listed claims cover the reference product itself or only a narrow formulation or method of use. A generic that uses the same strength and dosage form but changes nonessential excipients may avoid some formulation claims. It may still face bioequivalence, pharmaceutical-equivalence, labeling, and patent certification issues.

What manufacturing and intellectual-property barriers affect generic SKLICE?

The raw materials are commodities, but the finished product is not risk-free to reproduce. Development barriers include:

• Maintaining ivermectin uniformity in a semisolid or lotion matrix.
• Controlling phase separation during scale-up.
• Achieving reproducible viscosity and spreadability.
• Demonstrating preservative effectiveness.
• Controlling microbial quality in a water-containing product.
• Matching the reference product’s dosage form and performance.
• Establishing stability under temperature excursions.
• Validating packaging compatibility and extractables.
• Demonstrating equivalent delivery through hair and scalp.

For a topical generic, conventional pharmacokinetic bioequivalence may not fully capture local product performance. FDA may require comparative physicochemical characterization, in vitro release testing, comparative permeation data, or other product-specific evidence. The regulatory burden is higher than the ingredient list would suggest.[7]

Manufacturing scale can still be attractive. The formulation does not require a complex sterile process, lyophilization, cold chain, or biologic drug substance. A contract manufacturer with semisolid and lotion capability could produce the product at moderate cost, subject to validated controls.

What commercial opportunities exist around SKLICE excipients?

Preservative-free and low-preservative products

A preservative-free SKLICE-like product could target parents who avoid parabens. The main commercial benefit would be positioning, not necessarily clinical superiority. Unit-dose packaging, airless pumps, or sealed sachets could reduce contamination risk, but packaging costs would rise.

Foam and mousse delivery

A foam could improve distribution through thick or textured hair. The format could also reduce dripping and shorten application time. Development risks include propellant selection, flammability labeling, package performance, dose reproducibility, and scalp exposure uniformity.

Products for textured and long hair

SKLICE’s single-application regimen is commercially valuable, but application can be difficult in dense or long hair. A formulation with greater slip, lower residue, and improved root coverage could support premium pricing. Isopropyl myristate, ester blends, volatile silicones, or alternative emollients could be evaluated, subject to safety and regulatory compatibility.

Pediatric packaging

Because the product is labeled for children six months and older, packaging has commercial value. A metered-dose pump, child-resistant closure, clearer fill-volume indicator, or treatment cap could reduce use errors and improve household convenience.

Combination products

A combination of ivermectin with another pediculicide could broaden activity or address resistance concerns. Such a product would require new clinical, toxicological, labeling, and regulatory work. It would not be a simple excipient optimization.

International commercialization

Ivermectin topical products may be regulated differently outside the United States. The primary commercial opportunities are private-label licensing, regional distribution, and local formulation adaptation. Differences in preservative restrictions, pediatric labeling, OTC status, and permitted claims can affect product design and registration strategy.

How does SKLICE compare with competing head-lice products?

SKLICE competes with permethrin, pyrethrin-piperonyl butoxide, spinosad, malathion, and benzyl alcohol products. Ivermectin’s key commercial differentiator is the single 10-minute application without a mandatory nit-combing step in the labeled instructions.

Product class	Typical commercial advantage	Excipient opportunity
Ivermectin lotion	Single application and broad consumer recognition	Better spreadability, preservative alternatives, foam delivery
Permethrin lotion	Low cost and broad availability	Private-label scale and improved scalp feel
Spinosad suspension	Prescription efficacy and no nit combing	Suspension stability and pediatric acceptability
Malathion lotion	Established treatment option	Odor reduction and flammability management
Benzyl alcohol lotion	Non-neurotoxic mechanism	Improved rinseability and lower irritation
Pyrethrin products	OTC access and low price	Fragrance, residue, and sensitive-scalp positioning

SKLICE’s competitive exposure is greatest in retail channels where price and availability outweigh branded formulation differences. Its strongest defense is brand recognition, OTC distribution, the single-use message, and consumer familiarity.

What generic launch scenarios exist for SKLICE?

Authorized-generic or private-label launch

This is the lowest technical-risk route. A product could use a closely matched formulation and compete on price or retailer control. The principal risks are commercial margin compression and limited differentiation.

Conventional ANDA launch

A generic applicant could pursue an ANDA referencing SKLICE, subject to current FDA requirements and Orange Book certifications. Launch timing would depend on listed patents, regulatory review, first-filer status, and any litigation.

180-day first-filer opportunity

If an applicant submits a valid Paragraph IV certification and is first to file, it may become eligible for 180-day generic exclusivity, depending on the statutory and regulatory posture of the reference product. The value of that position depends on the number of competing filers and the enforceability of listed patents.

505(b)(2) differentiated product

A foam, spray, or materially different lotion could use a 505(b)(2) strategy if it relies partly on FDA findings for ivermectin while requiring new investigations. This route could support product differentiation but would involve greater development cost and potential patent certifications.

What is the revenue exposure and commercial value of the SKLICE franchise?

Revenue exposure depends on the product’s retail share, pricing, payer mix, and competition. Because SKLICE is an OTC product, commercial risk is tied primarily to shelf placement, digital marketing, seasonal demand, and retailer economics rather than reimbursement formularies.

A simple exposure framework is:

Scenario	Commercial effect
No direct generic	Maintains premium brand pricing
One generic entrant	Retail price and share pressure
Multiple generics	Rapid erosion in price and distribution
Improved branded dosage form	Potential premium and line extension
Private-label licensing	Volume growth with lower unit margin
Retailer-exclusive product	Distribution expansion but lower brand control

The most defensible investment thesis is a lifecycle strategy built around delivery, packaging, and channel access rather than reliance on the existing excipient composition as a high barrier.

Key Takeaways

• SKLICE is a 0.5% ivermectin lotion approved for head-lice treatment in patients six months and older.
• Its excipient system uses common materials: water, glycerin, isopropyl myristate, fatty alcohols, citrate buffer, methylparaben, and propylparaben.
• The formulation is technically reproducible, but semisolid uniformity, preservation, stability, and topical performance create development work.
• The strongest excipient opportunities are improved lotions, foams, preservative-reduced products, textured-hair formulations, and pediatric packaging.
• Biosimilar risk does not apply because ivermectin is a small-molecule drug.
• Generic and Paragraph IV risk depends on current Orange Book listings, patent scope, expiration dates, and FDA requirements for topical bioequivalence.
• Patent protection based only on standard excipients is likely to be limited. Narrow claims covering composition ratios, manufacturing controls, or specific use parameters may be more relevant.
• Commercial value is driven by OTC distribution, brand recognition, single-application positioning, and retail execution.
• A differentiated 505(b)(2) product could create stronger lifecycle protection than a conventional generic, but at higher development and regulatory cost.

FAQs

Can a competitor copy the SKLICE inactive ingredients?

Yes, subject to regulatory requirements, patent review, and product-specific equivalence standards. The inactive ingredients are commercially available and do not by themselves create a significant supply barrier.

Is a paraben-free ivermectin lice lotion commercially viable?

Yes. It could appeal to consumers seeking paraben-free products, but the developer would need to validate microbial preservation, stability, packaging compatibility, and scalp tolerability.

Could an ivermectin foam qualify as a generic SKLICE product?

A materially different foam may not fit a conventional ANDA pathway cleanly. Depending on the formulation and FDA determination, a 505(b)(2) application may be more appropriate.

Does SKLICE have biosimilar competition?

No. Biosimilar rules apply to biological products. Ivermectin is a chemically synthesized or semisynthetic small-molecule drug and is subject to generic-drug frameworks.

Which excipient is most important for SKLICE differentiation?

Isopropyl myristate is the most strategically significant because it affects spreading, emollience, hair feel, and drug partitioning. Its commercial value comes from the complete formulation system rather than from the ingredient alone.

References

1. U.S. Food and Drug Administration. (2020). SKLICE (ivermectin) lotion, 0.5%: Prescribing information.
2. DailyMed. (2024). SKLICE- ivermectin lotion. National Library of Medicine.
3. U.S. Food and Drug Administration. (2012). FDA approves lotion to treat head lice.
4. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter treatment for head lice.
5. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations.
6. U.S. Patent and Trademark Office. (2024). Patent Center.
7. U.S. Food and Drug Administration. (2022). Draft guidance on acyclovir topical cream and other topical semisolid drug products: Product-specific bioequivalence recommendations.